Drug intelligence / Profile preview

HiCM-488

Development stage: Preclinical
Lead developer: Help Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

HiCM-488 is an allogeneic, off-the-shelf cell therapy product derived from induced pluripotent stem cells (iPSCs), developed by Help Therapeutics. It is specifically designed for the treatment of cardiovascular diseases. As an iPSC-based therapy, HiCM-488 is intended to function through tissue regeneration and replacement in the heart, rather than by targeting specific molecular pathways. The product is currently in the concept validation or preclinical stage of development, representing an early-stage approach to regenerative medicine for cardiac conditions.

Beyond the preview

Go deeper on HiCM-488.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HiCM-488.

Explore the full profile